Bank Of New York Mellon Corp Neu Base Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $71,512 - $168,315	-87,210 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$4.63 - $7.34 $165,249 - $261,971	-35,691 Reduced 29.04%	87,210 $417,000
Q1 2021 May 13, 2021	SELL	$6.92 - $12.36 $10,677 - $19,071	-1,543 Reduced 1.24%	122,901 $908,000
Q4 2020 Feb 09, 2021	BUY	$6.92 - $9.25 $228,602 - $305,573	33,035 Added 36.14%	124,444 $869,000
Q3 2020 Nov 12, 2020	BUY	$7.25 - $9.71 $180,844 - $242,206	24,944 Added 37.53%	91,409 $693,000

Q2 2020 Aug 12, 2020	BUY	$6.69 - $11.51 $444,650 - $765,012	66,465 New	66,465 $583,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.